Vaccex Inc. (fka VCEX)

[rstar]

Development pipeline

Vaccex is focused on the discovery, development and commercialization of sustained release delivery products for the treatment of solid tumors, with its most advanced program VX001 being prepared for clinical proof of concept studies in 2020. Vaccex and its collaborators are currently planning clinical studies for intra-tumoral delivery of sustained release formulations of potent anti-cancer agents in three program areas:

Metastasized colorectal cancer
Metastasized breast cancer
Personalized intra-tumoral therapies


Vaccex is developing therapies for metastatic colorectal and breast cancers using intra-tumoral delivery of a sustained release formulation of a TLR 7/8 agonist in combination with radiotherapy.

Globally more than 1 million people get colorectal cancer every year resulting in more than 715,000 deaths and breast cancer affects about 12% of women bringing these two types of cancer on the top 5 list of the most frequently occurring cancers. Treatment of these cancers can be aimed at cure or palliation depending on the stage of development.

General treatment includes early intervention surgery and chemotherapy/radiotherapy but late stage metastasized cancers can rarely be treated and chemotherapy or radiotherapy are offered as palliative treatments and to only marginally increase life expectancy.
VX001 administered intra-tumorally in combination with radiotherapy has demonstrated highly synergistic effects in several syngenic mouse models leading to complete tumor regression, long-term survival and prevention of later cancer reoccurrences. VX001 in combination with RT thus have a potential clinical window ranging from life-extending treatment to being curative for patients with solid tumor metastases.

Personalized intra-tumoral therapy

Our sustained release formulation is an effective vector for local administration of immunotherapy, and we have made the decision to branch into the growing field of individualized cancer treatments with VX001. VX001 is designed to create individualized therapies by allowing for monitoring the activation of the patient’s immune system as a response to release kinetics and dosing regimen. Identification of genes that are differentially expressed due to treatment and cellular immunoprofiling from biopsies facilitates pharmacodynamics/pharmacokinetics studies that can be correlated with matching or opposing gene expression and phenotype data from large patient databases and publications. Although not providing a guarantee for success, this approach aims at identifying biomarkers for responders to treatment and thus could lead to improved therapies and patient selection.
https://www.vaccex.com/kopi-af-partnering